Summary
Pharmaceuticals in Scandinavia industry profile provides top-line qualitative and quantitative summary information including: market size (value 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.
- The Scandinavian pharmaceuticals market had total revenues of $13.1m in 2018, representing a compound annual rate of change (CARC) of -2.6% between 2014 and 2018.
- The performance of the market is forecast to decline further but at a slower pace, with an anticipated CARC of -0.2% for the five-year period 2018-2023, which is expected to drive the market to a value of $13.0m by the end of 2023.
- Scandinavian pharmaceuticals market is driven by nationalized healthcare systems and a strong research-base.
Scope
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Scandinavia
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Scandinavia
- Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Scandinavia pharmaceuticals market with five year forecasts
Reasons to buy
- What was the size of the Scandinavia pharmaceuticals market by value in 2018?
- What will be the size of the Scandinavia pharmaceuticals market in 2023?
- What factors are affecting the strength of competition in the Scandinavia pharmaceuticals market?
- How has the market performed over the last five years?
- How large is Scandinavia’s pharmaceuticals market in relation to its regional counterparts?
'
Table of Contents
Executive Summary
Market value
Market value forecast
Geography segmentation
Market share
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market Segmentation
Geography segmentation
Market share
Market Outlook
Market value forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Novartis AG
Pfizer Inc
F. Hoffmann-La Roche Ltd
Sanofi SA
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine
List of Tables
Table 1: Scandinavia pharmaceuticals market value: $ billion, 2014-18
Table 2: Scandinavia pharmaceuticals market geography segmentation: $ billion, 2018
Table 3: Scandinavia pharmaceuticals market share: % share, by value, 2018
Table 4: Scandinavia pharmaceuticals market value forecast: $ billion, 2018-23
Table 5: Novartis AG: key facts
Table 6: Novartis AG: key financials ($)
Table 7: Novartis AG: key financial ratios
Table 8: Pfizer Inc: key facts
Table 9: Pfizer Inc: key financials ($)
Table 10: Pfizer Inc: key financial ratios
Table 11: F. Hoffmann-La Roche Ltd: key facts
Table 12: F. Hoffmann-La Roche Ltd: key financials ($)
Table 13: F. Hoffmann-La Roche Ltd: key financials (CHF)
Table 14: F. Hoffmann-La Roche Ltd: key financial ratios
Table 15: Sanofi SA: key facts
Table 16: Sanofi SA: key financials ($)
Table 17: Sanofi SA: key financials (€)
Table 18: Sanofi SA: key financial ratios
List of Figures
Figure 1: Scandinavia pharmaceuticals market value: $ billion, 2014-18
Figure 2: Scandinavia pharmaceuticals market geography segmentation: % share, by value, 2018
Figure 3: Scandinavia pharmaceuticals market share: % share, by value, 2018
Figure 4: Scandinavia pharmaceuticals market value forecast: $ billion, 2018-23
Figure 5: Forces driving competition in the pharmaceuticals market in Scandinavia, 2018
Figure 6: Drivers of buyer power in the pharmaceuticals market in Scandinavia, 2018
Figure 7: Drivers of supplier power in the pharmaceuticals market in Scandinavia, 2018
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Scandinavia, 2018
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Scandinavia, 2018
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Scandinavia, 2018
Figure 11: Novartis AG: revenues & profitability
Figure 12: Novartis AG: assets & liabilities
Figure 13: Pfizer Inc: revenues & profitability
Figure 14: Pfizer Inc: assets & liabilities
Figure 15: F. Hoffmann-La Roche Ltd: revenues & profitability
Figure 16: F. Hoffmann-La Roche Ltd: assets & liabilities
Figure 17: Sanofi SA: revenues & profitability
Figure 18: Sanofi SA: assets & liabilities
